JPRN-jRCT1080222730
Unknown
N/A
Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritis
Toyama Chemical Co., Ltd. (Current FUJIFILM Toyama Chemical Co., Ltd.)0 sites2,000 target enrollmentJanuary 29, 2015
ConditionsRheumatoid Arthritis
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Rheumatoid Arthritis
- Sponsor
- Toyama Chemical Co., Ltd. (Current FUJIFILM Toyama Chemical Co., Ltd.)
- Enrollment
- 2000
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with rheumatoid arthritis
- •All patients who take iguratimod
Exclusion Criteria
- •Pregnant women or women suspected of being pregnant
- •Patients with a serious liver disorder
- •Patients with peptic ulcer
- •Patients with known hypersensitivity to iguratimod or any of its
- •Patients receiving treatment with warfarin
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
N/A
Investigation of the clinical safety and efficacy of iguratimod in patients with rheumatoid arthritisRheumatoid ArthritisJPRN-jRCT1080222005Eisai Co., Ltd.2,000
Not Yet Recruiting
N/A
Investigation of the clinical safety and efficacy of favipiravir (Avigan tablets) in patients with novel or re-emerging influenza virus infectionsJPRN-jRCT1080223849FUJIFILM Toyama Chemical Co., Ltd. (Former Toyama Chemical Co., Ltd.)
Completed
N/A
Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic SeizuresJPRN-jRCT1080224672Eisai Co., Ltd.500
Completed
N/A
Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic SeizuresJPRN-jRCT1080224671Eisai Co., Ltd.3,750
Withdrawn
N/A
Clinical investigation of the safety and efficacy of ALIMAXX-B biliary stent for bile duct obstructioCBD obstructionmalignant biliary obstruction10018008NL-OMON31943Alveolus, Inc.10